0000899243-21-047115.txt : 20211207 0000899243-21-047115.hdr.sgml : 20211207 20211207163023 ACCESSION NUMBER: 0000899243-21-047115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211203 FILED AS OF DATE: 20211207 DATE AS OF CHANGE: 20211207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CRAVES FRED B CENTRAL INDEX KEY: 0001014095 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 211476358 MAIL ADDRESS: STREET 1: 750 BATTERY ST STREET 2: STE 600 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-03 0 0001157601 MADRIGAL PHARMACEUTICALS, INC. MDGL 0001014095 CRAVES FRED B C/O BAY CITY CAPITAL LLC, 1000 4TH STREET, SUITE 500 SAN RAFAEL CA 94901 1 0 1 0 Common Stock 2021-12-03 4 J 0 750270 0.00 D 1510521 I See Footnotes Common Stock 2021-12-03 4 J 0 49730 0.00 D 0 I See Footnotes Common Stock 2021-12-03 4 J 0 24172 0.00 D 1261 I See Footnotes Common Stock 364358 D Common Stock 15000 I See Footnote Common Stock 90000 I See Footnote Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. These securities were held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities previously held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC. Represents shares held indirectly by Dr. Craves through the Craves Family Foundation. Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust. Represents transfers, without the payment of any consideration, to their partners and employees. Includes 46,779 shares previously reported as indirectly held. /s/ Fred B. Craves 2021-12-07